350 rub
Journal №6 for 2015 г.
Article in number:
Morphological features of tumors and the matrix metalloproteinases in the blood plasma of patients with gastric cancer
Keywords: primary gastric cancer histology MMP-2 MMP-7 MMP-9 TIMP-2
Authors:
A.A. Ivannikov Ph.D. (Med.), Tambov Regional Cancer Clinical Dispensary, Tambov V.L. Chang Assistant, Department of Oncology, Topographic Anatomy and Operative Surgery, G.A. Derzhavin Tambov State University, Tambov E.S. Gershtein Dr.Sc. (Biol.), Professor, Moscow State University of Medicine and Dentistry Named After A.I. Evdokimov N.A. Ognerubov Dr.Sc. (Med.), Professor, Head, Department of Oncology, Topographic Anatomy and Operative surgery, G.A. Derzhavin Tambov State University, Tambov M.M. Dav-idov Ph.D. (Med.), N.N. Blokhin Russian Cancer Research Center, Moscow I.S. Stilidi Dr.Sc. (Med.), Professor, Corresponding Member of the RAS, N.N. Blokhin Russian Cancer Research Center, Moscow N.E. Kushlinskii Dr.Sc. (Med.), Professor, Corresponding Member of the RAS, Head, of the Department of Clinical Biochemistry and Laboratory Diagnosis, Moscow State University of Medicine and Dentistry Named After A.I. Evdokimov
Abstract:
The study was conducted in 91 primary gastric cancer patients stage I-IV, aged 16 to 84 years. All patients prior to treatment in the plasma was determined content of matrix metalloproteinases (MMP-2, MMP-7, MMP-9) and tissue inhibitor type 2 (TIMP-2). 73 (80.2 %) patients underwent surgical procedures in different volumes. The interrelation of the above markers with some morphological features of the structure of the tumor. MMP-7 levels in patients with LVI was significantly higher, when its median perstnevidnokletochnoy adenocarcinoma was, conversely, significantly smaller. The content of MMP-9 was significantly lower in tumor invasion of the submucosal layer, and the level of MMP-2 was also significantly decreased with increasing depth of tumor invasion from 300±17.5 ng/ml at the mucosal invasion to 243±23.2 ng/ml during the invasion in other organs.
Pages: 42-48
References

 

  1. Alexander C.M., Selvarajan S., Mudgett J., Werb Z. Stromelysin-1 regulates adipogenesis during mammary gland involution // J. Cell Biology. 2001. V. 152. № 4. P. 693-703.
  2. Brand K., Baker A.H., Perez-Canto A. et al. Treatment of colorectal liver metastases by adenoviral transfer of tissue inhibitor of metalloproteinases-2 into the liver tissue // Cancer Res. 2000. V. 60. № 20. P. 5723-5730.
  3. Celiker M.Y., Wang M., Atsidaftos E. et al. Inhibition of Wilms\' tumor growth by intramuscular administration of tissue inhibitor of metalloproteinases-4 plasmid DNA // Oncogene. 2001. V. 20. № 32. P. 4337-4343.
  4. Deryugina E.I., Quigley J.P. Pleiotropic roles of matrix metalloproteinases in tumor angiogenesis: contrasting, overlapping and compensatory functions // Biochim. Biophys. Acta. 2010. V. 1803. № 1. P. 103-120.
  5. Hanahan D., Weinberg R.A. The hallmarks of cancer. The next generation // Cell. 2011. V. 144. № 4. P. 646-674.
  6. Kemik O., Kemik A.S., Sumer A. et al. Levels of matrix metalloproteinase-1 and tissue inhibitors of metalloproteinase-1 in gastric cancer // World J. Gastroenterol. 2011. V. 17. № 16. P. 2109-2112.
  7. Kim J.S., Kim M.A., Kim T.M. et al. Biomarker analysis in stage III-IV (M0) gastric cancer patients who received curative surgery followed by adjuvant 5-fluorouracil and cisplatin chemotherapy: epidermal growth factor receptor (EGFR) associated with favourable survival // Br. J. Cancer. 2009. V. 100. № 5. P. 732-738.
  8. Kim M., Kim H.J., Choi B.Y. et al. Identification of potential serum biomarkers for gastric cancer by a novel computational method, multiple normal tissues corrected differential analysis // Clin. Chim. Acta. 2012. V. 413. № 3-4. P. 428-433.
  9. Malemud C.J. Matrix metalloproteinases (MMPs) in health and disease: an overview // Front Biosci. 2006. V. 11. P. 1696-1701.
  10. Murphy G., Nagase H. Progress in matrix metalloproteinase research // Mol. Aspects. Med. 2008. V. 29. № 5. P. 290-308.
  11. Nelson A.R., Fingleton B., Rothenberg M.L., Matrisian L.M. Matrix metalloproteinases: biologic activity and clinical implications // J. Clin. Oncol. 2000. V. 18. № 5. P. 1135-1149.
  12. Ramnath N., Creaven P.J. Matrix metalloproteinase inhibitors // Curr. Oncol. Rep. 2004. V. 6. № 2. P. 96-102.
  13. Visse R., Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry // Circ. Res. 2003. V. 92. № 8. P. 827-839.
  14. Westermarck J., Kahari V.M. Regulation of matrix metalloproteinase expression in tumor invasion // FASEB J. 1999. V. 13. № 8. P. 781-792.
  15. Woessne J.F., Nagase Jr., Anonymous H.Matrix Metalloproteinases and TIMPs. 1. New York: Oxford University Press. 2000.